Boston Scientific's Obsidio embolic occluded all target vessels in 125-patient U.S. registry
Boston Scientific's Obsidio embolic occluded 100% of target vessels in the 125-patient OCCLUDE registry; the FDA approves Infilbray for type 3 Gaucher disease and Livsayis, the first siRNA therapy for myasthenia gravis.
FDA approves Gazyva as first treatment for primary membranous nephropathy
The FDA approves Gazyva as the first treatment for primary membranous nephropathy; AstraZeneca's weekly self-injected Klygefa is approved for myasthenia gravis and CMS extends its hospice enrollment moratorium.